ROCHE HOLDING AG

ROG
Delayed Quote. Delayed  - 11/26 11:31:16 am
358.6CHF -0.95%

Roche : FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19

10/14/2021 | 07:42am
Investor Update FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19

Dear Investor,

Please find attached a press release from our partner Regeneron:
https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-review

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Disclaimer

Roche Holding AG published this content on 14 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 October 2021 11:41:08 UTC.

© Publicnow 2021
Copier lien
All news about ROCHE HOLDING AG
1d ago
1d ago
1d ago
1d ago
1d ago